Chronic Hand Eczema Linked to High Costs, Corticosteroid Overuse

Why It Matters

The findings spotlight a costly, steroid‑dependent treatment paradigm that jeopardizes patient safety and strains payer budgets, while signaling a market opening for targeted CHE therapies that could curb expenses and improve outcomes.

Key Takeaways

• 86% of CHE patients used systemic corticosteroids over 3.5 years
• Pharmacy costs dominate, reaching $21,682 PPPY for JAK/monoclonal therapy
• Only 0.3% received oral JAK inhibitors despite high disease burden
• Delgocitinib approved July 2025 as first CHE‑specific therapy
• 45% had multiple eczema subtypes; 92% with advanced therapy

Pulse Analysis

Chronic hand eczema remains a hidden cost driver in dermatology, with the new claims study exposing a treatment landscape dominated by corticosteroids despite well‑documented safety risks. Over a 3.5‑year follow‑up, more than eight in ten patients relied on systemic steroids, a pattern that not only raises concerns about hypertension, adrenal suppression, and cardiovascular events but also inflates pharmacy expenditures. The analysis shows a steep cost gradient: patients on low‑intensity regimens incur roughly $1,900 annually, while those escalated to biologics or oral JAK inhibitors generate over $21,000 in yearly spending, underscoring the financial pressure on both patients and insurers.

The July 2025 FDA approval of delgocitinib cream marks a pivotal shift, introducing the first therapy specifically labeled for moderate‑to‑severe CHE. As a topical pan‑JAK inhibitor, delgocitinib offers a steroid‑sparing alternative that could curb the high systemic‑steroid usage highlighted in the study. For pharmaceutical firms, this creates a clear market entry point, while payers may anticipate reduced long‑term costs if the drug delivers durable disease control and lowers the need for expensive biologics. Early adoption data will be critical to assess whether delgocitinib can truly disrupt the entrenched steroid‑centric paradigm.

Managed‑care stakeholders must now weigh the clinical benefits of delgocitinib against its pricing, especially given the study’s revelation that pharmacy costs dominate CHE expenditures. Incorporating disease‑specific guidelines and encouraging appropriate use of the new therapy could improve patient quality of life, diminish comorbid mental‑health burdens, and ultimately achieve cost containment. Ongoing real‑world evidence will be essential to track shifts in treatment patterns post‑approval and to validate whether targeted therapies can deliver the promised reductions in both clinical risk and economic strain.